Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Viggle Announces Pricing of $4.2 Million Underwritten Sale of Common Stock to a Single Institutional Investor
-
Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering
-
Blue Earth (BBLU) Enters 1.67M Common Stock, Warrants Direct Offering
-
Blue Earth Announces $2 Million Registered Direct Offering
-
Immune Pharma (IMNP) Announces Date to Commence Bertilimumab Phase II Bullous Pemphigoid Trial
-
Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid
-
Ritter Pharmaceuticals (RTTR) IPO Opens Flat
-
Ritter Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
-
Chardan Capital Markets Upgrades Avalanche Biotechnologies (AAVL) to Neutral
-
Chardan Capital Starts Signal Genetics (SGNL) at Buy; MyPRS Test Could See Big Demand
-
Ritter Pharmaceuticals (RTTR) Amends IPO Filing; Plans to Offer 4M Shares and Sees Price of $5/Share
-
Notable Analyst Rating Changes 6/18: (JNPR) (HOG) (AMC) Upgraded; (RATE) (LUV) (NMBL) Downgraded
-
Pre-Open Stock Movers 06/18: (LMNS) (DGLY) (BMRN) Higher; (HERO) (RATE) (ORCL) Lower (more...)
-
Chardan Capital Starts VistaGen Therapeutics (VSTA) at Buy; Positive on AV-101 as Antidepressant Sans Ketamine Side Effects
-
Chardan Capital Markets Starts Axovant Sciences (AXON) at Sell; RVT-101 Remains Overrated
-
Chardan Capital Markets Starts Digital Ally (DGLY) at Buy; FirstVu Should be Key Source of Growth
-
Chardan Capital Trims PT on Profire Energy (PFIE) to $1.80; FY16 Outlook 'Sharply' Lower than Expected
-
Chardan Capital Markets Downgrades Avalanche Biotechnologies (AAVL) to Sell
-
Esperion Therapeutics (ESPR) Price Target Lowered to $50 at Chardan
-
Chardan Capital Markets Upgrades MaxLinear (MXL) to Buy
-
Chardan Capital Boosts PT on Ambarella (AMBA) to $90; Stock Continues Defying Conventional Wisdom
-
22nd Century Group Announces Closing of $6 Million Registered Direct Offering
-
StemCells, Inc. Announces Closing of Over-Allotment Option
-
Notable Analyst Rating Changes 5/29: (MX) (CPRT) Upgraded; (HIMX) (ANF) (URI) Downgraded
-
Pre-Open Stock Movers 05/29: (TBIO) (HRTX) (NQ) Higher; (FRO) (SPLK) (CYBR) Lower (more...)
-
UPDATE: Chardan Capital Markets Cuts Himax Technologies (HIMX) to Sell; Samsung Moving to AMOLED Would be Huge Blow
-
Chardan Capital Markets Starts Amicus Therapeutics (FOLD) at Buy
-
22nd Century Group (XXII) Enters 6M Common Stock, 3M Warrants Registered Direct Offering
-
22nd Century Group Announces $6 Million Registered Direct Offering
-
Notable Analyst Rating Changes 5/22: (RWLK) (BAH) (DOV) Upgraded; (GD) (JGW) (CONN) Downgraded
-
Chardan Capita Starts Esperion Therapeutics (ESPR) at Sell; Post-IPO Run Leads to Unfavorable Risk-Reward
-
Chardan Capital Markets Starts Esperion Therapeutics (ESPR) at Sell
-
REGENXBIO Secures $70.5 Million in a Mezzanine Financing
-
REGENXBIO Secures $70.5 Million in a Mezzanine Financing
-
Chardan Capital Lifts PT on Immune Pharma (IMNP) to $6 Following Q1 Report; AmiKet Appears on Track
-
Camtek Ltd (CAMT) Prices 4.3M Common Offering at $2.85/Share
-
Camtek Prices Underwritten Public Offering of Ordinary Shares
-
CORRECTION - Camtek Ltd: Camtek Prices Underwritten Public Offering of Ordinary Shares
-
NeuroVive Pharmaceutical: NeuroVive Completes Share Issue Raising SEK 70 Million for the Preparation of CicloMulsion®’s Clinical Trial in the US and Commercialization in Europe
-
Chardan Capital Markets Starts U.S. Geothermal (HTM) at Neutral
-
Chardan Capital Markets Upgrades CEVA Inc. (CEVA) to Buy
-
Chardan Capital Markets Starts Check-Cap (CHEK) at Buy
-
StemCells, Inc. Announces Closing of $25 Million Public Offering
-
Notable Analyst Rating Changes 4/29: (LLY) (VOD) (UPS) Upgraded; (GLW) (ETR) (NOV) Downgraded
-
Chardan Capital Markets Starts Lion Biotechnologies (LBIO) at Buy, PT $30
-
New C Media Partnership Demonstrates YOU On Demand's (YOD) Desire to Diversify - Chardan Capital
-
MassRoots Partners with Seed-to-Sale System Flowhub; Crosses 300 Dispensaries on Network
-
Notable Analyst Rating Changes 4/24: (MAT) (TEL) (CVC) Upgraded; (BBY) (NKE) (GM) Downgraded
-
Smoofi Announces Agreement With Licensed Cultivator in Colorado
-
StemCells (STEM) Prices Common, Warrants Offering at $0.70/Unit

